Company · CIK 0001454789 · SIC 2834 — Pharmaceutical Preparations
CATABASIS PHARMACEUTICALS INC · CATB
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 30, 2015 CForm 4 → | Jun 30, 6:48 pm EDT | Michael JirousekChief Scientific Officer | 67,067 | — | — | 246,093 | — | plan? |
| Jun 30, 2015 PForm 4 → | Jun 30, 6:47 pm EDT | Jean GeorgeDirector | 258,776 | $12.00 | $3,105,312 | 90,764 | — | plan? |
| Jun 30, 2015 CForm 4 → | Jun 30, 6:47 pm EDT | Jean GeorgeDirector | 1,632,076 | — | — | 78,342 | — | plan? |
| Jun 30, 2015 PForm 4 → | Jun 30, 6:47 pm EDT | Nicholas GalakatosDirector, 10% Owner | 376,695 | $12.00 | $4,520,340 | 2,752,488 | +15.9% | plan? |
| Jun 30, 2015 CForm 4 → | Jun 30, 6:47 pm EDT | Nicholas GalakatosDirector, 10% Owner | 2,375,793 | — | — | 2,375,793 | — | plan? |
| Jun 30, 2015 CForm 4 → | Jun 30, 6:47 pm EDT | Joanne M. DonovanChief Medical Officer | 409 | — | — | 409 | — | plan? |
| Jun 30, 2015 PForm 4 → | Jun 30, 6:47 pm EDT | Clarus Lifesciences II, L.P. +210% Owner | 376,695 | $12.00 | $4,520,340 | 2,752,488 | +15.9% | plan? |
| Jun 30, 2015 CForm 4 → | Jun 30, 6:47 pm EDT | Clarus Lifesciences II, L.P. +210% Owner | 2,375,793 | — | — | 2,375,793 | — | plan? |
| Jun 30, 2015 PForm 4 → | Jun 30, 6:46 pm EDT | SVLSF V, LLC +310% Owner | 391,090 | $12.00 | $4,693,080 | 59,139 | — | plan? |
| Jun 30, 2015 CForm 4 → | Jun 30, 6:46 pm EDT | SVLSF V, LLC +310% Owner | 2,466,577 | — | — | 51,045 | — | plan? |
| Jun 30, 2015 CForm 4 → | Jun 30, 6:46 pm EDT | Rick ModiChief Business Officer | 4,094 | — | — | 4,094 | — | plan? |
| Jun 30, 2015 CForm 4 → | Jun 30, 6:45 pm EDT | Jill C. MilnePresident and CEO, Director | 74,846 | — | — | 253,872 | — | plan? |
| Jun 30, 2015 PForm 4 → | Jun 30, 6:45 pm EDT | MedImmune Ventures, Inc.10% Owner | 223,439 | $12.00 | $2,681,268 | 1,632,652 | +15.9% | plan? |
| Jun 30, 2015 CForm 4 → | Jun 30, 6:45 pm EDT | MedImmune Ventures, Inc.10% Owner | 1,409,213 | — | — | 1,409,213 | — | plan? |
| Jun 30, 2015 PForm 4 → | Jun 30, 6:45 pm EDT | Ron LauferDirector, 10% Owner | 223,439 | $12.00 | $2,681,268 | 1,632,652 | +15.9% | plan? |
| Jun 30, 2015 CForm 4 → | Jun 30, 6:45 pm EDT | Ron LauferDirector, 10% Owner | 1,409,213 | — | — | 1,409,213 | — | plan? |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 13, 2019 AForm 4 → | Feb 15, 8:42 am EST | Deirdre A. CunnaneChief Legal Officer | 40,000 | — | — | 40,000 | — | |
| Feb 13, 2019 AForm 4 → | Feb 15, 8:41 am EST | Andrew John NicholsChief Scientific Officer | 40,000 | — | — | 40,000 | — | |
| Feb 13, 2019 AForm 4 → | Feb 15, 8:41 am EST | Joanne M. DonovanCMO; SVP Clinical Development | 40,000 | — | — | 40,000 | — | |
| Feb 13, 2019 AForm 4 → | Feb 15, 8:40 am EST | Jill C. MilneCEO and President, Director | 100,000 | — | — | 100,000 | — | |
| Feb 13, 2019 AForm 4 → | Feb 15, 8:37 am EST | Anthony Gregg LapointeDirector | 12,200 | — | — | 12,200 | — | |
| Feb 13, 2019 AForm 4 → | Feb 15, 8:36 am EST | Joanne T. BeckDirector | 15,000 | — | — | 15,000 | — | |
| Jan 3, 2019 AForm 4/A → | Jan 4, 4:04 pm EST | Anthony Gregg LapointeDirector | 2,800 | — | — | 2,800 | — | |
| Jan 3, 2019 AForm 4 → | Jan 4, 9:24 am EST | Anthony Gregg LapointeDirector | 2,800 | — | — | 2,800 | — | amended |
| Sep 7, 2018 AForm 4 → | Sep 11, 4:15 pm EDT | Deirdre A. CunnaneChief Legal Officer | 150,000 | — | — | 150,000 | — | |
| Sep 7, 2018 AForm 4 → | Sep 11, 4:14 pm EDT | Andrew John NicholsChief Scientific Officer | 150,000 | — | — | 150,000 | — | |
| Sep 7, 2018 AForm 4 → | Sep 11, 4:13 pm EDT | Joanne M. DonovanCMO; SVP Clinical Development | 150,000 | — | — | 150,000 | — | |
| Sep 7, 2018 AForm 4 → | Sep 11, 4:12 pm EDT | Jill C. MilneCEO and President, Director | 230,000 | — | — | 230,000 | — | |
| Jun 7, 2018 AForm 4 → | Jun 7, 6:19 pm EDT | Michael Jay RossDirector | 14,000 | — | — | 14,000 | — | |
| Jun 7, 2018 AForm 4 → | Jun 7, 6:07 pm EDT | Michael D KishbauchDirector | 14,000 | — | — | 14,000 | — | |
| Jun 7, 2018 AForm 4 → | Jun 7, 6:06 pm EDT | Burt A AdelmanDirector | 14,000 | — | — | 14,000 | — | |
| Jun 7, 2018 AForm 4 → | Jun 7, 6:05 pm EDT | Kenneth BateDirector | 14,000 | — | — | 14,000 | — | |
| Jun 7, 2018 AForm 4 → | Jun 7, 6:04 pm EDT | Jean GeorgeDirector | 14,000 | — | — | 14,000 | — | |
| Feb 8, 2018 AForm 4 → | Feb 9, 4:02 pm EST | Deirdre A. CunnaneSVP, General Counsel | 100,000 | — | — | 100,000 | — | |
| Feb 8, 2018 AForm 4 → | Feb 9, 4:02 pm EST | Andrew John NicholsChief Scientific Officer | 100,000 | — | — | 100,000 | — | |
| Feb 8, 2018 AForm 4 → | Feb 9, 4:02 pm EST | Joanne M. DonovanCMO; SVP Clinical Development | 100,000 | — | — | 100,000 | — | |
| Feb 8, 2018 AForm 4 → | Feb 9, 4:01 pm EST | Jill C. MilneCEO and President, Director | 230,000 | — | — | 230,000 | — | |
| Feb 8, 2018 AForm 4 → | Feb 9, 4:01 pm EST | Edward K. HibbenChief Business Officer | 100,000 | — | — | 100,000 | — | |
| Jul 27, 2017 AForm 4 → | Jul 28, 4:05 pm EDT | Kenneth BateDirector | 6,500 | — | — | 6,500 | — | |
| Jul 27, 2017 AForm 4 → | Jul 28, 4:05 pm EDT | Burt A AdelmanDirector | 6,500 | — | — | 6,500 | — | |
| Jul 27, 2017 AForm 4 → | Jul 28, 4:04 pm EDT | Michael D KishbauchDirector | 6,500 | — | — | 6,500 | — | |
| Jul 27, 2017 AForm 4 → | Jul 28, 4:03 pm EDT | Jean GeorgeDirector | 6,500 | — | — | 6,500 | — | |
| Jul 27, 2017 AForm 4 → | Jul 28, 4:02 pm EDT | Michael Jay RossDirector | 6,500 | — | — | 6,500 | — | |
| Feb 9, 2017 AForm 4 → | Feb 10, 4:07 pm EST | Deirdre A. CunnaneSVP, General Counsel | 100,000 | — | — | 100,000 | — | |
| Feb 9, 2017 AForm 4 → | Feb 10, 4:06 pm EST | Andrew John NicholsChief Scientific Officer | 100,000 | — | — | 100,000 | — | |
| Feb 9, 2017 AForm 4 → | Feb 10, 4:05 pm EST | Joanne M. DonovanCMO; SVP Clinical Development | 100,000 | — | — | 100,000 | — | |
| Feb 9, 2017 AForm 4 → | Feb 10, 4:04 pm EST | Jill C. MilneCEO and President, Director | 200,000 | — | — | 200,000 | — | |
| Oct 3, 2016 AForm 4 → | Oct 5, 4:08 pm EDT | Andrew John NicholsChief Scientific Officer | 13,000 | — | — | 13,000 | — | |
| Sep 8, 2016 AForm 4/A → | Sep 13, 5:25 pm EDT | Deirdre A. CunnaneSVP, General Counsel | 45,000 | — | — | 45,000 | — | |
| Sep 8, 2016 AForm 4/A → | Sep 13, 5:24 pm EDT | Rick ModiChief Business Officer | 45,000 | — | — | 45,000 | — | |
| Sep 8, 2016 AForm 4/A → | Sep 13, 5:24 pm EDT | Joanne M. DonovanCMO; SVP Clinical Development | 45,000 | — | — | 45,000 | — | |
| Sep 8, 2016 AForm 4/A → | Sep 13, 5:24 pm EDT | Jill C. MilneCEO and President, Director | 45,000 | — | — | 45,000 | — | |
| Sep 8, 2016 AForm 4 → | Sep 12, 4:17 pm EDT | Joanne M. DonovanCMO; SVP Clinical Development | 45,000 | — | — | 45,000 | — | amended |
| Sep 8, 2016 AForm 4 → | Sep 12, 4:14 pm EDT | Jill C. MilneCEO and President, Director | 45,000 | — | — | 45,000 | — | amended |
| Sep 8, 2016 AForm 4 → | Sep 12, 4:13 pm EDT | Rick ModiChief Business Officer | 45,000 | — | — | 45,000 | — | amended |
| Sep 8, 2016 AForm 4 → | Sep 12, 4:12 pm EDT | Deirdre A. CunnaneSVP, General Counsel | 45,000 | — | — | 45,000 | — | amended |
| Aug 3, 2016 AForm 4 → | Aug 5, 4:09 pm EDT | Nicholas GalakatosDirector | 6,500 | — | — | 6,500 | — | |
| Aug 3, 2016 AForm 4 → | Aug 5, 4:08 pm EDT | Jean GeorgeDirector | 6,500 | — | — | 6,500 | — | |
| Aug 3, 2016 AForm 4 → | Aug 5, 4:08 pm EDT | Kenneth BateDirector | 6,500 | — | — | 6,500 | — | |
| Aug 3, 2016 AForm 4 → | Aug 5, 4:08 pm EDT | Michael Jay RossDirector | 6,500 | — | — | 6,500 | — | |
| Apr 5, 2016 AForm 4 → | Apr 7, 4:11 pm EDT | Michael D KishbauchDirector | 13,000 | — | — | 13,000 | — | |
| Apr 5, 2016 AForm 4 → | Apr 7, 4:10 pm EDT | Burt A AdelmanDirector | 13,000 | — | — | 13,000 | — | |
| Feb 11, 2016 AForm 4 → | Feb 16, 6:30 pm EST | Jill C. MilnePresident and CEO, Director | 103,000 | — | — | 103,000 | — | |
| Feb 11, 2016 AForm 4 → | Feb 16, 6:27 pm EST | Ian C. SandersonChief Financial Officer | 52,000 | — | — | 52,000 | — | |
| Feb 11, 2016 AForm 4 → | Feb 16, 6:25 pm EST | Rick ModiChief Business Officer | 42,000 | — | — | 42,000 | — | |
| Feb 11, 2016 AForm 4 → | Feb 16, 6:23 pm EST | Joanne M. DonovanChief Medical Officer | 66,000 | — | — | 66,000 | — | |
| Feb 11, 2016 AForm 4 → | Feb 16, 6:18 pm EST | Deirdre A. CunnaneSVP, General Counsel | 23,000 | — | — | 23,000 | — | |
| Jul 17, 2015 AForm 4 → | Jul 21, 4:02 pm EDT | Jill C. MilnePresident and CEO, Director | 160,000 | — | — | 160,000 | — | |
| Jun 30, 2015 CForm 4 → | Jun 30, 6:48 pm EDT | Michael JirousekChief Scientific Officer | 861,832 | — | — | 0 | — | |
| Jun 30, 2015 ACForm 4 → | Jun 30, 6:47 pm EDT | Jean GeorgeDirector | 20,983,356 | — | — | 11,094 | — | |
| Jun 30, 2015 ACForm 4 → | Jun 30, 6:47 pm EDT | Nicholas GalakatosDirector, 10% Owner | 30,540,065 | — | — | 11,094 | — | |
| Jun 30, 2015 CForm 4 → | Jun 30, 6:47 pm EDT | Joanne M. DonovanChief Medical Officer | 5,261 | — | — | 0 | — | |
| Jun 30, 2015 CForm 4 → | Jun 30, 6:47 pm EDT | Clarus Lifesciences II, L.P. +210% Owner | 30,528,971 | — | — | 0 | — | |
| Jun 30, 2015 AForm 4 → | Jun 30, 6:46 pm EDT | Kenneth BateDirector | 11,094 | — | — | 11,094 | — | |
| Jun 30, 2015 CForm 4 → | Jun 30, 6:46 pm EDT | SVLSF V, LLC +310% Owner | 31,695,610 | — | — | 0 | — | |
| Jun 30, 2015 AForm 4 → | Jun 30, 6:46 pm EDT | Michael Jay RossDirector | 11,094 | — | — | 11,094 | — | |
| Jun 30, 2015 CForm 4 → | Jun 30, 6:46 pm EDT | Rick ModiChief Business Officer | 52,614 | — | — | 0 | — | |
| Jun 30, 2015 CForm 4 → | Jun 30, 6:45 pm EDT | Jill C. MilnePresident and CEO, Director | 961,777 | — | — | 0 | — | |
| Jun 30, 2015 CForm 4 → | Jun 30, 6:45 pm EDT | MedImmune Ventures, Inc.10% Owner | 18,108,446 | — | — | 0 | — | |
| Jun 30, 2015 ACForm 4 → | Jun 30, 6:45 pm EDT | Ron LauferDirector, 10% Owner | 18,119,540 | — | — | 11,094 | — |